News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
French Neovasc Inc. Cuts IPO Ambitions
April 9, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- French biotech company Neovacs on Friday lowered its capital raising ambitions for an initial public offering (IPO) this month to 11 million euros, instead of the 20 million euros previously sought.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Alzheimer’s disease
Sanofi’s Neuro Push Arrives in Seoul With $1B+ Alzheimer’s Play
December 16, 2025
·
1 min read
·
Tristan Manalac
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
December 10, 2025
·
1 min read
·
Annalee Armstrong
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
December 9, 2025
·
2 min read
·
Dan Samorodnitsky
